Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Manhattan Associates Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Manhattan Associates Inc trades at $216.88 (market cap $12.99B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Manhattan Associates Inc for 11 Days on average.
| KYMR | MANH | |
|---|---|---|
Market Cap | $8.87B | $12.99B |
Volume | 779,107 | 546,880 |
Sector | Health | Technology |
52-Week High | $127.31 | $223.76 |
52-Week Low | $55.80 | $120.88 |
Typical Hold Time | 0 Days | 11 Days |
Enterprise Value | $8.26B | $12.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MANH trades at $222.71, up 2.21% today, with a bullish technical signal and strong profitability metrics including a 96.38% ROE. Recent earnings have consistently beaten expectations, and the company launched new Editions solutions to expand market access. However, high valuation ratios and a legal investigation pose headwinds.
The outlook remains positive with 80% analyst buy ratings and a $219.25 consensus target, but risks include elevated P/E of 63.81 and potential fiduciary breach concerns. Earnings growth and product innovation are key catalysts, yet investors should weigh valuation against legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
